SOURCE: Helix BioPharma Corp.

Helix BioPharma Corp.

July 26, 2016 07:15 ET

AACR Approves Helix BioPharma Corp's Poster for Presentation at the International Cancer Immunotherapy Conference

Urease-Mediated Alkalization of Tumor Microenvironment and Its Effects on T Cell Proliferation, Cytokine Release and PD-1/PD-L1 Interactions

AURORA, ON--(Marketwired - Jul 26, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: Urease-mediated alkalization of tumor microenvironment and its effects on T cell proliferation, cytokine release and PD-1/PD-L1 interactions, has been accepted for presentation at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being held in New York City on September 25th and 26th, 2016 at the Hilton Midtown-Grand America. The presentation will be given on September 25th at 5:00pm. A copy of the presentation will be available on the Company's website on the date of the presentation.

"We are delighted to have our immuno-oncology research efforts recognized by the AACR and we look forward to sharing the results of our research with the larger oncology research community," said Dr. Heman Chao, Chief Scientific Officer. 

About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties
This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential benefits of Helix's DOS47 platform in the treatment of cancer. Forward-looking statements, which may be identified by words including, without limitation, "will", "potential", "benefits" and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. 

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Contact Information